Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 August 1994 | Volume 121 Issue 3 | Pages 198-199
Contrast-enhanced pituitary computed tomographic (CT) scans were normal. Abdominal CT scans and magnetic resonance imaging studies showed that both adrenal glands were diffusely enlarged but that the pancreas seemed normal. An enhanced axial CT scan of the chest with 5-mm-thick slices showed no abnormality. Somatostatin receptor imaging done after intravenous administration of 20 µg of Indium-111-pentetreotide (222 MBq) showed a focus of increased activity in the left upper lobe, parahilar in location Figure 1 a, as early as 4 hours after the injection of the tracer. This focus was evident for at least an additional 20 hours thereafter. Repeat CT scanning of the chest with coronal reconstruction of the left upper lobe showed a central 1-cm rounded mass occluding a subsegmental bronchus of the apicoposterior segment of the left upper lobe. Distal to the mass, a wedge-shaped small zone of air trapping was noted Figure 1 b.
BRIEF COMMUNICATION
Localization of Adrenocorticotropic Hormone-secreting Bronchial Carcinoid Tumor by Somatostatin-Receptor Scintigraphy
Most ectopic adrenocorticotropic hormone (ACTH)-secreting tumors are bronchial carcinoids [1], and many are malignant [2]. Intensive localization studies are therefore warranted. However, frequently, and especially in small centrally located tumors, various imaging modalities are inconclusive. Recently, somatostatin receptor scintigraphic studies using the radiolabeled long-acting somatostatin analog Indium-111-pentetreotide (Mallinckrodt Medical, Pettem, the Netherlands) have enabled the detection of medullary thyroid carcinoma and islet cell tumor, both secreting ACTH. However, a small ACTH-secreting bronchial carcinoid was not similarly identified [3]. We describe a patient with ACTH-producing malignant bronchial carcinoid in whom octreotide scintigraphy led to localization of the tumor and its successful resection.
Case Report
![]()
Top
Case Report
Discussion
Author & Article Info
References
A 22-year-old woman presented with a 3-month history of postpartum amenorrhea. Physical examination showed a blood pressure of 190/100 mm Hg, moon facies, and truncal obesity. Prominent purple striae covered her abdominal and chest walls. No goiter was palpable. Laboratory data included serum cortisol concentrations of 966 nmol/L at 0800 h (normal, 138 to 552 nmol/L) and 828 nmol/L at 2000 h (normal, 55 to 414 nmol/L). The plasma ACTH level at 0800 h was 60 pmol/L (normal, 2.3 to 13.8 pmol/L). Urinary free cortisol excretion was 1269 nmol/24 h (normal, 30 to 300 nmol/24 h). Dexamethasone administration of up to 16 mg daily in four equally divided doses did not significantly suppress serum cortisol and plasma ACTH levels or urinary free cortisol excretion. Cortisol and ACTH levels were both determined using commercially available kits (cortisol: DPC, Los Angeles, California; ACTH: Nichols Institute, San Juan Capistrano, California).
|
Left upper lobectomy showed a typical invasive carcinoid and metastatic foci within one lymph node. Immunocytochemical staining of specimens from both the tumor and the metastatic lymph node was positive for ACTH. The plasma ACTH concentration was 33 pmol/L in the pulmonary artery feeding the tumor and 64 pmol/L in the pulmonary vein draining the tumor.
One month after surgery, the patient showed marked clinical improvement. Without any medication, her blood pressure was 120/80 mm Hg. The morning cortisol level after 1-mg overnight dexamethasone administration was 30 nmol/L (normal, <138 nmol/L).
Discussion
|
|---|
|
|
|---|
Several neuroendocrine tumors, including those secreting ACTH, have somatostatin receptors [7] and respond clinically and biochemically to administration of the long-acting somatostatin analog octreotide [8]. Nevertheless, some ACTH-secreting tumors do not have these receptors and do not respond to octreotide treatment [3, 9]. Recently, the interaction of Indium-111-pentetreotide with ACTH-secreting bronchial carcinoid has been reported in two cases. In one case, the carcinoid proved to be devoid of somatostatin receptors both on autoradiography and on scintigraphy [3]. In the second case, which has been reported only in abstract form, scintigraphic studies with Indium-111-pentetreotide showed the carcinoid [10]. It thus appears that the inconsistent detection of ACTH-secreting bronchial carcinoids depends on the degree of somatostatin-receptor expression in these tumors. This expression can be identified in vivo by a radiolabeled somatostatin analog. Our findings suggest that in cases of obscure ectopic ACTH-producing tumor, somatostatin-receptor scintigraphic study is warranted because it may localize the tumor for surgical removal or indicate which patients need octreotide treatment.
Addendum
|
|---|
Author and Article Information
|
|---|
|
|
|---|
References
|
|---|
|
|
|---|
1. Doppman JL, Nieman L, Miller DL, Pass HI, Chang R, Cutler GB Jr, et al. Ectopic adrenocorticotropic hormone syndrome: localization studies in 28 patients. Radiology. 1989; 172:115-24.
2. Leinung MC, Young WF Jr, Whitaker MD, Scheithauer BW, Trastek VF, Kvols LK. Diagnosis of corticotropin-producing bronchial carcinoid tumors causing Cushing's syndrome. Mayo Clin Proc. 1990; 65:1314-21.
3. Lamberts SW, Hofland LJ, de Herder WW, Kwekkeboom DJ, Reubi JC, Krenning EP. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy. Front Neuroendocrinol. 1993; 14:27-55.
4. van Noorden S, Varndell IA. Regulatory peptide immunocytochemistry at light- and electron microscopical levels. Experientia. 1987; 43:724-34.
5. Jex RK, van Heerden JA, Carpenter PC, Grant CS. Ectopic ACTH syndrome. Diagnostic and therapeutic aspects. Am J Surg. 1985; 149:276-82.
6. Findling JW. Eutopic or ectopic adrenocorticotropic hormone-dependent Cushing's syndrome? A diagnostic dilemma (Editorial). Mayo Clin Proc. 1990; 65:1377-80.
7. Lamberts SW. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev. 1988; 9:417-36.
8. Hearn PR, Reynolds CL, Johansen K, Woodhouse NJ. Lung carcinoid with Cushing's syndrome: control of serum ACTH and cortisol levels using SMS 201-950 (sandostatin). Clin Endocrinol Oxf. 1988; 28:181-5.
9. Cheung NW, Boyages SC. Failure of somatostatin analogue to control Cushing's syndrome in two cases of ACTH-producing carcinoid tumours. Clin Endocrinol Oxf. 1992; 36:361-7.
10. Colombo P, Paganelli G, Magnani C, Fazio F, Faglia G. Scintigraphic studies with radiolabelled somatostatin analogue and anti-chromogranin A antibodies in patients with pituitary adenomas and ectopic Cushing's syndrome. J Endocrinol Invest 1993; 16(Suppl 1 to no. 8):S5.
11. Phlipponneau M, Nocaudie M, Epelbaum J, DeKeyzer Y, Lalau JD, Marchandise X, et al. Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropin-secreting bronchial carcinoid tumor. J Clin Endocrinol Metab. 1994; 78:20-4.
This article has been cited by other articles:
![]() |
G. Arnaldi, T. Mancini, B. Kola, G. Appolloni, S. Freddi, C. Concettoni, I. Bearzi, A. Masini, M. Boscaro, and F. Mantero Cyclical Cushing's Syndrome in a Patient with a Bronchial Neuroendocrine Tumor (Typical Carcinoid) Expressing Ghrelin and Growth Hormone Secretagogue Receptors J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5834 - 5840. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Tsagarakis, M. Christoforaki, H. Giannopoulou, F. Rondogianni, I. Housianakou, C. Malagari, D. Rontogianni, I. Bellenis, and N. Thalassinos A Reappraisal of the Utility of Somatostatin Receptor Scintigraphy in Patients with Ectopic Adrenocorticotropin Cushing's Syndrome J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4754 - 4758. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kwekkeboom, E. P. Krenning, and M. de Jong Peptide Receptor Imaging and Therapy J. Nucl. Med., October 1, 2000; 41(10): 1704 - 1713. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Rosado de Christenson, G. F. Abbott, W. M. Kirejczyk, J. R. Galvin, and W. D. Travis From the Archives of the AFIP: Thoracic Carcinoids: Radiologic-Pathologic Correlation RadioGraphics, May 1, 1999; 19(3): 707 - 736. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. TORPY, C. C. CHEN, N. MULLEN, J. L. DOPPMAN, J. A. CARRASQUILLO, G. P. CHROUSOS, and L. K. NIEMAN Lack of Utility of 111In-Pentetreotide Scintigraphy in Localizing Ectopic ACTH Producing Tumors: Follow-Up of 18 Patients J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1186 - 1192. [Abstract] [Full Text] |
||||
![]() |
A. Tabarin, N. Valli, P. Chanson, Y. Bachelot, V. Rohmer, V. Bex-Bachellerie, B. Catargi, P. Roger, and F. Laurent Usefulness of Somatostatin Receptor Scintigraphy in Patients with Occult Ectopic Adrenocorticotropin Syndrome J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1193 - 1202. [Abstract] [Full Text] |
||||
![]() |
W W DE HERDER and S W J LAMBERTS Octapeptide somatostatin-analogue therapy of Cushing's syndrome Postgrad. Med. J., February 1, 1999; 75(880): 65 - 66. [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||